Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease

Figure 2

Comparison of diameter stenosis among the groups (). (a) At 4-week follow-up. (b) At 8-week follow-up. G1 (group 1): bare-metal stent (BMS), G2 (group 2): drug-free hybrid stent, G3 (group 3): 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and G4 (group 4): 30% PTX/PLGA (slow PTX-releasing form) hybrid stent.

(a)

(b)